Anti-CTLA4, Tremelimumab, inhibits the action of CTLA4 and blocks the T-cell suppression, and also stimulates the development of cytokines like IL-2 and interferon-gamma (IFN-γ) thereby improving the responsiveness of the immune system to fight against different cancers like renal cancer, melanoma and non-small cell lung cancer (NSCLC) (Fu et al., 2024). This evidence concerns the gene IL2 and non-small cell lung carcinoma.